☰

Matthew L. Rizk, Ph.D. - Publications

Affiliations: 
2009 University of California, Los Angeles, Los Angeles, CA 
Area:
Chemical and Biomolecular Engineering
Tree Info Similar researchers PubMed Report error

7/51 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2011 Rizk ML, Laguna R, Smith KM, Tabita FR, Liao JC. Redox homeostasis phenotypes in RubisCO-deficient Rhodobacter sphaeroides via ensemble modeling. Biotechnology Progress. 27: 15-22. PMID 20939096 DOI: 10.1002/Btpr.506  0.575
2010 Dean JT, Rizk ML, Tan Y, Dipple KM, Liao JC. Ensemble modeling of hepatic fatty acid metabolism with a synthetic glyoxylate shunt. Biophysical Journal. 98: 1385-95. PMID 20409457 DOI: 10.1016/J.Bpj.2009.12.4308  0.519
2009 Rizk ML, Liao JC. Ensemble modeling for aromatic production in Escherichia coli. Plos One. 4: e6903. PMID 19730732 DOI: 10.1371/Journal.Pone.0006903  0.588
2009 Contador CA, Rizk ML, Asenjo JA, Liao JC. Ensemble modeling for strain development of L-lysine-producing Escherichia coli. Metabolic Engineering. 11: 221-33. PMID 19379820 DOI: 10.1016/J.Ymben.2009.04.002  0.572
2009 Rizk ML, Liao JC. Ensemble modeling and related mathematical modeling of metabolic networks Journal of the Taiwan Institute of Chemical Engineers. 40: 595-601. DOI: 10.1016/J.Jtice.2009.05.003  0.595
2008 Tran LM, Rizk ML, Liao JC. Ensemble modeling of metabolic networks. Biophysical Journal. 95: 5606-17. PMID 18820235 DOI: 10.1529/Biophysj.108.135442  0.635
2008 Rizk ML, Tran LM, Liao JC. Ensemble modeling of metabolic networks and identification of enzyme targets for metabolic engineering Aiche Annual Meeting, Conference Proceedings.  0.574
Low-probability matches (unlikely to be authored by this person)
2021 van den Berg P, Gao W, Ahsman MJ, Arrington L, Kesisoglou F, Miller R, Post TM, Rizk ML. Understanding effect site pharmacology of uprifosbuvir, a HCV nucleoside inhibitor: case study of a multidisciplinary modelling approach in drug development. Cpt: Pharmacometrics & Systems Pharmacology. PMID 33934558 DOI: 10.1002/psp4.12644  0.259
2019 Bhagunde P, Zhang Z, Racine F, Carr D, Wu J, Young K, Rizk ML. A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam. International Journal of Infectious Diseases : Ijid : Official Publication of the International Society For Infectious Diseases. PMID 31479762 DOI: 10.1016/j.ijid.2019.08.026  0.171
2018 Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, Katwaru R, Si Q, Harradine P, Motyl M, Bhagunde PR, Rizk ML. Relebactam (MK-7655) in combination with imipenem: Exploring the pharmacokinetic/pharmacodynamic relationship with a hollow fiber infection model. Antimicrobial Agents and Chemotherapy. PMID 29507068 DOI: 10.1128/AAC.02323-17  0.151
2015 Rizk ML, Du L, Bennetto-Hood C, Wenning L, Teppler H, Homony B, Graham B, Fry C, Nachman S, Wiznia A, Worrell C, Smith B, Acosta EP. Population pharmacokinetic analysis of raltegravir pediatric formulations in HIV-infected children 4 weeks to 18 years of age. Journal of Clinical Pharmacology. 55: 748-56. PMID 25753401 DOI: 10.1002/Jcph.493  0.142
2024 Maas BM, Strizki J, Miller RR, Kumar S, Brown M, Johnson MG, Cheng M, De Anda C, Rizk ML, Stone JA. Molnupiravir: Mechanism of action, clinical, and translational science. Clinical and Translational Science. 17: e13732. PMID 38593352 DOI: 10.1111/cts.13732  0.136
2023 Chawla A, Birger R, Wan H, Cao Y, Maas BM, Paschke A, De Anda C, Rizk ML, Stone JA. Factors Influencing COVID-19 Risk: Insights from Molnupiravir Exposure-Response Modeling of Clinical Outcomes. Clinical Pharmacology and Therapeutics. PMID 37017631 DOI: 10.1002/cpt.2895  0.12
2018 Rizk ML, Rhee EG, Jumes PA, Gotfried MH, Zhao T, Mangin E, Bi S, Chavez-Eng CM, Zhang Z, Butterton JR. Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-lactamase Inhibitor, Dosed in Combination with Imipenem/Cilastatin in Healthy Subjects. Antimicrobial Agents and Chemotherapy. PMID 29311084 DOI: 10.1128/AAC.01411-17  0.12
2024 Shahin MH, Rizk ML. Patient-Centric Clinical Pharmacology: A Journey from Discovery to Recovery. Clinical Pharmacology and Therapeutics. 115: 928-930. PMID 38629339 DOI: 10.1002/cpt.3243  0.12
2023 Bihorel S, Cao Y, Chawla A, Birger R, Maas BM, Gao W, Roepcke S, Sardella S, Humphrey R, Kondragunta S, Jayaraman B, Martinho M, Painter W, Painter G, Holman W, ... ... Rizk ML, et al. Population pharmacokinetics of molnupiravir in adults with COVID-19: Lack of clinically important exposure variation across individuals. Cpt: Pharmacometrics & Systems Pharmacology. PMID 37798914 DOI: 10.1002/psp4.13031  0.112
2018 Aulin LBS, Valitalo PA, Rizk ML, Visser SAG, Rao G, van der Graaf PH, van Hasselt JGC. Validation of a Model Predicting Anti-infective Lung Penetration in the Epithelial Lining Fluid of Humans. Pharmaceutical Research. 35: 26. PMID 29368211 DOI: 10.1007/s11095-017-2336-7  0.104
2020 Carr D, Zhang Z, Si Q, Racine F, Xiao JC, Katwaru R, Wismer MK, Johnson MG, Feng HP, Young K, Rizk ML, Motyl M. In Vitro Hollow-Fiber Studies Assessing Antibacterial Activity of Ceftolozane/Tazobactam Against Multidrug-Resistant . Open Forum Infectious Diseases. 7: ofaa469. PMID 33241064 DOI: 10.1093/ofid/ofaa469  0.089
2015 Välitalo PA, Griffioen K, Rizk ML, Visser SA, Danhof M, Rao G, van der Graaf PH, van Hasselt JG. Structure-Based Prediction of Anti-infective Drug Concentrations in the Human Lung Epithelial Lining Fluid. Pharmaceutical Research. PMID 26626793 DOI: 10.1007/s11095-015-1832-x  0.082
2014 Rizk ML, Houle R, Chan GH, Hafey M, Rhee EG, Chu X. Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation. Antimicrobial Agents and Chemotherapy. 58: 1294-301. PMID 24295974 DOI: 10.1128/AAC.02049-13  0.079
2019 Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML. Ceftolozane/tazobactam population pharmacokinetics and dose selection for further clinical evaluation in pediatric patients with complicated urinary tract or complicated intraabdominal infections. Antimicrobial Agents and Chemotherapy. PMID 30962340 DOI: 10.1128/AAC.02578-18  0.079
2021 Patel M, Bellanti F, Daryani NM, Noormohamed N, Hilbert DW, Young K, Kulkarni P, Copalu W, Gheyas F, Rizk ML. Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital-acquired/ventilator-associated bacterial pneumonia. Clinical and Translational Science. PMID 34704389 DOI: 10.1111/cts.13158  0.076
2017 Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR. Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical Pharmacokinetics. PMID 28185217 DOI: 10.1007/s40262-017-0517-5  0.075
2021 Li D, Sabato PE, Guiastrennec B, Ouerdani A, Feng HP, Duval V, De Anda CS, Sears PS, Chou MZ, Hardalo C, Broyde N, Rizk ML. Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients With Acute Bacterial Skin and Skin Structure Infections. Antimicrobial Agents and Chemotherapy. AAC0089521. PMID 34516243 DOI: 10.1128/AAC.00895-21  0.074
2018 Lala M, Brown M, Kantesaria B, Walker B, Paschke A, Rizk ML. Simplification of Imipenem Dosing by Removal of Weight-Based Adjustments. Journal of Clinical Pharmacology. PMID 30536420 DOI: 10.1002/jcph.1356  0.072
2020 Nicol MR, Joshi A, Rizk ML, Sabato PE, Savic RM, Wesche D, Zheng JH, Cook J. Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection. Clinical Pharmacology and Therapeutics. PMID 32687630 DOI: 10.1002/cpt.1993  0.07
2016 Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. Phase 2, Dose-Ranging Study of Relebactam with Imipenem/Cilastatin in Subjects with Complicated Intra-Abdominal Infection. Antimicrobial Agents and Chemotherapy. PMID 27503659 DOI: 10.1128/Aac.00633-16  0.067
2020 Ang JY, Arrieta A, Bradley JS, Zhang Z, Yu B, Rizk ML, Johnson MG, Rhee EG. Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient Population. American Journal of Perinatology. PMID 31910460 DOI: 10.1055/s-0039-3402719  0.066
2016 Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR. A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir. Clinical Pharmacokinetics. PMID 27699622 DOI: 10.1007/s40262-016-0458-4  0.062
2019 Bhagunde P, Colon-Gonzalez F, Liu Y, Wu J, Xu SS, Garrett G, Jumes P, Lasseter K, Marbury T, Rizk ML, Lala M, Rhee EG, Butterton JR, Boundy K. Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety, and tolerability of relebactam combined with imipenem and cilastatin PK of relebactam and imipenem/cilastatin. British Journal of Clinical Pharmacology. PMID 31856304 DOI: 10.1111/bcp.14204  0.061
2012 Rizk ML, Hang Y, Luo WL, Su J, Zhao J, Campbell H, Nguyen BY, Sklar P, Eron JJ, Wenning L. Pharmacokinetics and pharmacodynamics of once-daily versus twice-daily raltegravir in treatment-naive HIV-infected patients. Antimicrobial Agents and Chemotherapy. 56: 3101-6. PMID 22430964 DOI: 10.1128/AAC.06417-11  0.058
2016 Krishna R, Rizk ML, Larson PJ, Schulz V, Friedman E, Gupta P, Kesisoglou F, Connor A, McDermott J, Smith R, Evans P. Novel Gastroretentive Controlled Release Formulations for Once-Daily Administration: Assessment of Clinical Feasibility and Formulation Concept for Raltegravir. Therapeutic Innovation & Regulatory Science. 50: 777-790. PMID 30231748 DOI: 10.1177/2168479016657130  0.057
2018 Trame MN, Riggs M, Biliouris K, Marathe D, Mettetal J, Post TM, Rizk ML, Visser SAG, Musante CJ. A Perspective on the State of Pharmacometrics and Systems Pharmacology Integration. Cpt: Pharmacometrics & Systems Pharmacology. PMID 29761892 DOI: 10.1002/psp4.12313  0.057
2017 Krishna R, Rizk ML, Larson P, Schulz V, Kesisoglou F, Pop R. Single- and Multiple-Dose Pharmacokinetics of Once-Daily Formulations of Raltegravir. Clinical Pharmacology in Drug Development. PMID 28419778 DOI: 10.1002/cpdd.358  0.056
2020 Titov I, Wunderink RG, Roquilly A, Rodríguez Gonzalez D, David-Wang A, Boucher HW, Kaye KS, Losada MC, Du J, Tipping R, Rizk ML, Patel M, Brown ML, Young K, Kartsonis NA, et al. A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32785589 DOI: 10.1093/cid/ciaa803  0.053
2018 Kakara M, Larson K, Feng HP, Shiomi M, Yoshitsugu H, Rizk ML. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection. Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy. PMID 30528208 DOI: 10.1016/j.jiac.2018.11.005  0.052
2012 Sun L, Li H, Willson K, Breidinger S, Rizk ML, Wenning L, Woolf EJ. Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trial. Analytical Chemistry. 84: 8614-21. PMID 23030780 DOI: 10.1021/ac301581h  0.05
2016 van Hasselt JG, Rizk ML, Lala M, Chavez-Eng C, Visser SA, Kerbusch T, Danhof M, Rao G, van der Graaf PH. Pooled population pharmacokinetic model of imipenem in plasma and the lung epithelial lining fluid. British Journal of Clinical Pharmacology. PMID 26852277 DOI: 10.1111/bcp.12901  0.049
2019 Bhagunde P, Patel P, Lala M, Watson K, Copalu W, Xu M, Kulkarni P, Young K, Rizk ML. Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections. Cpt: Pharmacometrics & Systems Pharmacology. PMID 31508899 DOI: 10.1002/psp4.12462  0.047
2014 Clarke DF, Acosta EP, Rizk ML, Bryson YJ, Spector SA, Mofenson LM, Handelsman E, Teppler H, Welebob C, Persaud D, Cababasay MP, Wang J, Mirochnick M. Raltegravir pharmacokinetics in neonates following maternal dosing. Journal of Acquired Immune Deficiency Syndromes (1999). 67: 310-5. PMID 25162819 DOI: 10.1097/Qai.0000000000000316  0.046
2019 Feng HP, Guo Z, Fandozzi C, Panebianco D, Caro L, Wolford D, Dreyer DP, Valesky R, Martinho M, Rizk ML, Iwamoto M, Yeh WW. Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants. Clinical Pharmacology in Drug Development. PMID 31173673 DOI: 10.1002/cpdd.702  0.046
2018 Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination With Imipenem and Cilastatin in Healthy Participants. Antimicrobial Agents and Chemotherapy. PMID 29914955 DOI: 10.1128/Aac.00280-18  0.045
2020 Arrieta AC, Ang JY, Zhang Z, Larson KB, Yu B, Johnson MG, Rhee EG, Feng EH, Rizk ML. Plasma pharmacokinetics of ceftolozane/tazobactam in pediatric patients with cystic fibrosis. Pediatric Pulmonology. PMID 32421928 DOI: 10.1002/ppul.24815  0.044
2020 Boundy K, Liu Y, Bhagunde P, O'Reilly TE, Colon-Gonzalez F, Friedman EJ, Lala M, Rhee EG, Rizk ML. Thorough QTc Study of a Single Supratherapeutic Dose of Relebactam in Healthy Participants. Clinical Pharmacology in Drug Development. PMID 32212418 DOI: 10.1002/cpdd.786  0.044
2018 Bradley JS, Ang JY, Arrieta AC, Larson KB, Rizk ML, Caro L, Yang S, Yu B, Johnson MG, Rhee EG. Pharmacokinetics and Safety of Single Intravenous Doses of Ceftolozane/Tazobactam in Children with Proven or Suspected Gram-Negative Infection. The Pediatric Infectious Disease Journal. PMID 30153232 DOI: 10.1097/INF.0000000000002170  0.039
2018 Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants". Antimicrobial Agents and Chemotherapy. 62. PMID 30478180 DOI: 10.1128/Aac.02197-18  0.035
2023 Roberts JA, Nicolau DP, Martin-Loeches I, Deryke CA, Losada MC, Du J, Patel M, Rizk ML, Paschke A, Chen LF. Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. Jac-Antimicrobial Resistance. 5: dlad011. PMID 36880088 DOI: 10.1093/jacamr/dlad011  0.03
2021 Nicolau DP, De Waele J, Kuti JL, Caro L, Larson KB, Yu B, Gadzicki E, Zeng Z, Rhee EG, Rizk ML. Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. International Journal of Antimicrobial Agents. 106299. PMID 33567333 DOI: 10.1016/j.ijantimicag.2021.106299  0.029
2014 Rhee EG, Rizk ML, Brainard DM, Gendrano IN, Jin B, Wenning LA, Wagner JA, Iwamoto M. A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adults. Antiviral Therapy. 19: 619-24. PMID 24608069 DOI: 10.3851/IMP2765  0.029
2011 Eron JJ, Rockstroh JK, Reynes J, Andrade-Villanueva J, Ramalho-Madruga JV, Bekker LG, Young B, Katlama C, Gatell-Artigas JM, Arribas JR, Nelson M, Campbell H, Zhao J, Rodgers AJ, Rizk ML, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial. The Lancet. Infectious Diseases. 11: 907-15. PMID 21933752 DOI: 10.1016/S1473-3099(11)70196-7  0.027
2015 Nachman S, Alvero C, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Rizk ML, Spector SA, Frenkel LM, Worrell C, Handelsman E, Wiznia A. Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age. Journal of the Pediatric Infectious Diseases Society. 4: e76-83. PMID 26582887 DOI: 10.1093/Jpids/Piu146  0.025
Hide low-probability matches.